TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04347096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention
Description: The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
Study: NCT00671567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Study: NCT00345033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 15-mg dose once a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet placebo dose once a day for 8 weeks
Study: NCT02970045

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, and other biological samples

Intervention type: PROCEDURE
Intervention: Evaluation of Cancer Risk Factors
Description: Ancillary studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04511611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 10 mg as 1 x 10 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 10 mg as 1 x 10 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 10 mg as 1 x 10 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 10 mg as 1 x 10 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 10 mg as 1 x 10 mg film-coated tablet
Study: NCT01413412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair using mesh
Description: 25 patients
Study: NCT02797015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Description: Oral capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Description: Oral capsule daily
Study: NCT00132639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel-cisplatin combination chemotherapy
Description: Preoperative docetaxel-cisplatin combination chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative docetaxel monotherapy
Description: Preoperative docetaxel monotherapy
Study: NCT04137432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 international units oxytocin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contains identical ingredients except for the peptide itself.
Study: NCT00316771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 150mg
Description: 150mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 25mg
Description: 25mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 300mg
Description: 300mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 50mg
Description: 50mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 75mg
Description: 75mg po bid
Study: NCT04511611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 10 mg as 1 x 10 mg film-coated tablet
Study: NCT00316771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study: NCT03563287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail of nine CYP probe drugs
Description: Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules.
Study: NCT02122848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiLevel
Description: The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
Study: NCT01218503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICES - obese
Description: Standard group behavioral weight loss treatment
Study: NCT01974947

Intervention type: OTHER
Intervention: Blood sample, sperm sample and clinical examens
Description: Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
Study: NCT01809379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with doxorubicin and cisplatin
Description: intraperitoneal chemotherapy applied as an aerosol and under pressure
Study: NCT01474538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Insulin lispro (100 U/mL) administered by CSII pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Insulin aspart (100 U/mL) administered by CSII pump
Study: NCT03422991

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and Quality of life questionnaire.
Description: Blood sampling and Quality of life questionnaire.
Study: NCT01520324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral delivery mucosal stain
Description: 200mg methylene blue MMX tablet taken prior to colonoscopy
Study: NCT01734993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
Study: NCT00114972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent
Description: Drug Eluting Stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Surgery
Description: Coronary Artery Bypass Surgery
Study: NCT00916526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial provocation test with mannitol
Description: Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered.
Study: NCT03523663

Intervention type: OTHER
Intervention: no intervention. measure eye movement data

Intervention type: OTHER
Intervention: no intervention. measure eye movement data
Study: NCT00773591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Study: NCT02533648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 capsules of allopurinol 150 mg daily for 3 month
Description: 2 capsules of allopurinol 150 mg daily for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 capsules of lactose daily for 3 month
Description: 2 capsules of lactose daily for 3 month
Study: NCT00415350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin Tablet 250 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 1 daily
Study: NCT04559308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: first-line anti-diabetic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: First line neoadjuvant chemotherapy protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First line neoadjuvant chemotherapy protocol
Study: NCT01979055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Description: 6 session educational intervention (3 telephone, 3 In-person), led by a health educator

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone follow-up
Description: Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
Study: NCT00147251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved drugs to treat blood pressure and cholesterol
Study: NCT01933958

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
Study: NCT03283111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: autologous stem cell transplantation
Study: NCT05318014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular nutrition education
Description: dietitian regular nutrition educataion which was following a low protein diet
Study: NCT03664661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA nanobody CAR-T cells
Description: step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Study: NCT03153956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated AposTherapy®
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Calibrated Sham Apos Therapy Device
Description: The comparator group will receive a non-calibrated sham device.
Study: NCT02642029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excitatory TMS
Description: Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory TMS
Description: Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
Study: NCT03886766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
Study: NCT03918889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injectable Product
Description: dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
Study: NCT04240470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
Study: NCT01588639

Intervention type: DRUG
Intervention: Insulin (Scilin N, BAY81-9924)
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.

Intervention type: DRUG
Intervention: Insulin (Scilin R _BAY81-9924
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice

Intervention type: DRUG
Intervention: Insulin(Scilin M30_BAY81-9924)
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
Study: NCT04256096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
Study: NCT04152707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splendor X
Description: The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
Study: NCT00773591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Study: NCT00992927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule-Preserving Intra-articular Hydraulic Distension
Description: Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
Study: NCT02776176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Program
Description: optimized peri-operative protocol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Program
Description: traditional standard protocol
Study: NCT02395627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Study: NCT04511611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 10 mg as 1 x 10 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 10 mg as 1 x 10 mg film-coated tablet
Study: NCT00731991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: ART to the levator scapulae.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: PNF to the levator scapulae.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment
Description: No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
Study: NCT03323411

Intervention type: BEHAVIORAL
Intervention: Advance Care Treatment Plan
Description: subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
Study: NCT03460899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euglycaemic Clamp
Description: All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
Study: NCT01323660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25
Description: 125mcg/ 25mcg QID (Once daily , inhaled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25
Description: 125mcg/ 25mcg QID (Once daily , inhaled)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719/GW642444 125/25
Description: 125mcg/ 25mcg QID (Once daily , inhaled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5mcg/25mcg QID
Study: NCT03460899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic/Hypoglycaemic Clamp
Description: All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
Study: NCT04134637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 5 MG/ML
Description: twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
Study: NCT04079452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy
Description: Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
Study: NCT00992927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule-Rupturing Intra-articular Hydraulic Distension
Description: Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
Study: NCT03886766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
Study: NCT03585348

Intervention type: OTHER
Intervention: Neuromuscular blocking agents
Description: Neuromuscular blocking agent ED95 equivalent dose by provider
Study: NCT02860455

Intervention type: DEVICE
Group type: OTHER
Intervention: RAD57 measurement (SpCO)
Description: SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin.

Intervention type: DEVICE
Group type: OTHER
Intervention: CO-oximeter
Description: COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin.
Study: NCT04064385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.